Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with Type 1 diabetes
Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with Type 1 diabetes
复制标题
DOI：
10.1007/s00125-004-1365-z
复制
发表时间：
2004-04-01
期刊：
影响因子：
8.2
通讯作者：
Gall, MA
中科院分区：
文献类型：
--
作者：
Hermansen, K;Fontaine, P;Gall, MA
目的/假说。该试验的目的是比较两种类型的基础灌注治疗的疗效和耐受性，使用可溶性长效基础胰岛素类似物，地特米特胰岛素，与速效类似物，胰岛素分离，或NPH胰岛素与餐时常规人胰岛素联合使用。在这项为期18周的1:1随机、开放标签、平行试验中，595例1型糖尿病患者分别在早晨和睡前接受地特胰岛素或NPH胰岛素，并在进餐时联合使用分离胰岛素或常规人胰岛素。与NPH胰岛素/常规人胰岛素(HbA(1)c: 7.88% vs 8.11%；平均差值：-0.22%点[95% CI: -0.34至-0.10]；p
Aims/hypothesis. The aim of the trial was to compare the efficacy and tolerability of two types of basal-bolus therapy, using either the soluble long-acting basal insulin analogue, insulin detemir, in combination with the rapid-acting analogue, insulin aspart, or NPH insulin in combination with mealtime regular human insulin.Methods. In this 18-week, 1:1 randomised, open-labelled, parallel trial, 595 patients with Type 1 diabetes mellitus received insulin detemir or NPH insulin in the morning and at bedtime in combination with mealtime insulin aspart or regular human insulin respectively.Results. Glycaemic control with insulin detemir/insulin aspart was improved in comparison with NPH insulin/regular human insulin (HbA(1)c: 7.88% vs 8.11%; mean difference: -0.22% point [95% CI: -0.34 to -0.10]; p